With respect to host genetic factors, variations in the IL28B gene affect the progression of CHC due to HCV exposure14,15, and variations in the ITPA gene are associated with the outcomes of interferon and ribavirin combination therapy16. This evidence concerns the gene IFNL3 and cryohydrocytosis.